91 results about "Aortic aneurysm" patented technology

The invention discloses an abdominal aortic aneurysm progress prediction method and system based on cross-modal knowledge distillation. The method comprises the following steps: collecting blood of a target object; the method comprises the following steps: detecting the concentration of blood protein fingerprint markers of blood of a target object, wherein the blood protein fingerprint markers comprise matrix metalloproteinase-12, calcitonin-related polypeptide-alpha, uromodulin, nerve injury induction protein-1, glycosylated hemoglobin A1c and fibroblast growth factor-9; carrying out abdominal aortic aneurysm risk calculation by calling Student-net of cross-modal knowledge distillation based on the blood protein fingerprint marker concentration; wherein the input of the Teaser-net of the cross-modal knowledge distillation comprises a CTA image feature and a pathological section feature, and a category probability vector output by the Student-net is aligned with a category probability vector output by the Teaser-net; and outputting the risk level of the abdominal aortic aneurysm and the probability of occurrence / progress / rupture of the abdominal aortic aneurysm in the preset year. And the development of the aortic aneurysm disease is accurately predicted.

The invention discloses an abdominal aortic aneurysm risk screening method based on HbA1c multiple risk markers, and aims to solve the problems that AAA screening in the prior art depends on a single marker, is lack of nonlinear analysis and is insufficient in application tool, a comprehensive risk prediction model is constructed by integrating HbA1c, proteomics data and non-genetic factors, a nonlinear risk relationship is revealed, and the risk of the abdominal aortic aneurysm is predicted to be the risk of the abdominal aortic aneurysm of the abdominal aortic aneurysm of the abdominal aortic aneurysm. And an application tool is developed, visual display of the morbidity probability and the risk level of n years is provided, a personalized screening strategy is supported, and the accuracy and practicability of AAA early screening are improved.

The invention discloses a screening method of a protein marker combination, which is used for risk prediction of abdominal aortic aneurysm or ruptured abdominal aortic aneurysm, and optimizes the stability of a protein expression profile by constructing an initial protein expression profile; screening differential expression proteins by adopting statistical analysis, and preliminarily locking candidate proteins remarkably associated with a disease endpoint based on survival analysis or a risk regression model; performing cross validation by combining a sparse constraint algorithm and a nonlinear feature selection algorithm, and extracting a robust core marker; the independent contribution degree of each marker is evaluated through the standardized weight, and finally the optimal protein combination for disease prediction or diagnosis is determined. According to the method, six core proteins obtained through multi-algorithm cross screening can be detected in serum, multivariable logistic regression and external verification set performance both show good robustness, and an aorta protein fingerprint feature set which can be popularized and explained is formed.

A method for providing information about the possibility of abdominal aortic aneurysm occurrence according to an embodiment of the present invention comprises the steps of: receiving an input of a plurality of pieces of demographic information and personal clinical information; generating an abdominal aortic aneurysm occurrence prediction model by performing training on the basis of the demographic information and the personal clinical information; inputting demographic information and personal clinical information about a subject to the abdominal aortic aneurysm occurrence prediction model; and outputting information about the possibility of abdominal aortic aneurysm occurrence in the subject from the abdominal aortic aneurysm occurrence prediction model.

The invention relates to the technical field of medical instruments, and provides a drug delivery balloon system for aortic aneurysm, a drug delivery balloon is a hollow balloon, and a blood flow channel for blood to pass through is arranged in the axial extension direction of the drug delivery balloon; the drug delivery balloon comprises a balloon outer surface and a balloon inner surface, wherein the balloon outer surface is provided with micropores for allowing drugs to pass through; the balloon inner surface and the balloon outer surface are correspondingly arranged to form a balloon main body, and a hollow inner cavity of the balloon main body is a blood flow channel; a filling pipeline communicated with the balloon main body is arranged on the peripheral wall of the balloon catheter, and the filling pipeline is used for conveying liquid medicine and / or a contrast agent into the balloon main body so as to fill the balloon main body. By arranging the filling pipeline at the end part of the drug delivery balloon with a hollow structure, the filling work of the balloon main body can be realized. Therefore, when the drug delivery balloon system is used for treating aortic aneurysm, blood vessels are ensured to be unobstructed, blood flow is not blocked, and balloon drug delivery work is completed at the same time.

The application belongs to the technical field of biological medicine, and relates to application of a CXCL14 inhibitor in preparation of a drug for preventing or treating abdominal aortic aneurysm of a patient. The inhibitor effectively eliminates the gender difference of abdominal aortic aneurysm by specifically blocking the combination of CXCL14 and its receptor CXCR4, significantly reduces aortic macrophage infiltration and PDGFRA + macrophage accumulation in the progress of abdominal aortic aneurysm, reduces the degree of collagen degradation and elastic fiber damage, and thus inhibits the pathological progress of abdominal aortic aneurysm. The application provides a new target and drug combination for precise treatment of male abdominal aortic aneurysm, and has clear clinical application value.

The invention discloses an application of methylene blue in preparation of drugs for preventing and treating aortic dissection and aortic aneurysm, which proves that after methylene blue is orally taken in an aortic aneurysm mouse model, expansion of aortic diameter can be inhibited and occurrence rate of aortic dissection and aortic aneurysm can be reduced after methylene blue is given. Abnormal aorta dilatation of mice and disorder and fracture of elastic fibers caused by BAPN water drinking are improved. Therefore, the death rate of the BAPN-induced aortic dissection and aortic aneurysm mice can be reduced and the disease progress of the aortic dissection and aortic aneurysm can be delayed by giving the methylene blue, so that the expansion condition of the aorta of the mice is improved and the survival rate is increased.

The present invention relates to a self-expanding stent (1) for implantation in the abdominal aorta of a human body for the treatment of abdominal aortic aneurysm, the stent (1) comprising an expandable framework (2) formed from a shape memory alloy and having a distal end (4), a proximal end (6), and an interior volume extending along a central axis from the distal end (4) to the proximal end (6), the framework (2) having at least a distal end ring (8) and a proximal end ring (10) with peaks (12) and valleys (13), and optionally at least one ring (14, 15) disposed between the distal end ring (8) and the proximal end ring (10), the framework (2) having a length LF from the distal end (4) to the proximal end (6) of at least 10 mm, the stent having a compressed state having a minimum diameter (Dmin), an expanded state having a nominal diameter (DN), and a relaxed state having a maximum diameter (Dmax). According to the present invention, at least one of the distal ring (8), the proximal ring (10), and the optional rings (14, 15) of the stent (1) exhibits a nominal radial resistance pressure (RRP-N) of 100 mmHg or greater at a nominal diameter (DN). The present invention also relates to a method.

The utility model discloses an aorta intracavitary stent with an external expansion balloon, and belongs to the technical field of medical instruments. Comprising a covered stent, at least one degradable balloon is arranged on the outer side of the covered stent in the length direction, and the degradable balloon is filled with hydrogel. According to the aorta intracavitary stent with the external expansion balloon, the degradable balloon is arranged outside the covered stent, the hydrogel is filled in the degradable balloon, and the anchoring capacity of the stent to blood vessels can be improved through the external expansion balloon at the early stage; in the later stage, the balloon releases the internal hydrogel through self-degradation or under the action of external force, expands after being in contact with blood, and allows fibroblasts and the like to enter and grow, so that thrombosis of the aortic aneurysm can be promoted, and a tumor cavity can be stabilized.

1. Name of the product in this design: Packaging box for early risk warning kit for abdominal aortic aneurysm. 2. Purpose of this design: For the outer packaging of an early risk warning kit for abdominal aortic aneurysm. 3. The key design feature of this product is its pattern. 4. The image or photograph that best illustrates the design's key features: the front view.

The invention relates to the technical field of biological medicines, and particularly relates to a method for researching the influence of silencing or inhibiting a UBE2G1 gene on the growth of abdominal aortic aneurysm by constructing a UBE2G1 gene function deletion mouse model. Results show that silence or inhibition of UBE2G1 gene expression can inhibit growth of abdominal aortic aneurysm, alleviate destruction of elastic fibers of arterial tissues, reduce levels of inflammatory factors such as TNF-alpha, IL-1beta and IL-6 in a body and inhibit polarization of macrophage M1. According to the invention, a certain theoretical basis is provided in the aspect of treatment of abdominal aortic aneurysm by means of biotechnology, and the UBE2G1 gene (or protein) can be used as a drug target for treatment of abdominal aortic aneurysm.

The invention belongs to the technical field of gene therapy and biological medicine, and particularly provides application of leucine in preparation of a medicine for preventing and / or treating aortic aneurysm. The leucine is independently used or is combined with other medicines for preventing and / or treating aortic aneurysm. The activity of GLUD1 is enhanced through leucine, so that conversion of Glu to alpha-KG is promoted, degradation of Glu is promoted, namely, the Glu level is reduced by enhancing degradation of Glu, and aortic aneurysm is improved. In a Glu metabolic network, Gln can be converted into Glu under the action of glutaminase 1 (GLS1), so that the generation of Glu is inhibited by inhibiting the activity of GLS1, and the effect of preventing and / or treating aortic aneurysm is achieved.

To provide simple yet accurate stent graft fenestration, a patient-specific fenestration template is used as a guide for graft fenestration. To generate the fenestration template, a patient's medical imaging data such as CT scan data may be used to generate a 3-D digital model of an aorta lumen of the patient. The aorta lumen may encompass one or more branch vessels, which may be indicated on the 3-D digital model. Based on the 3-D digital model or a segment thereof, the fenestration template may be generated, for example, using 3-D printing technology. The fenestration template may include one or more holes or openings that correspond to the one or more branch vessels. To fenestrate a stent graft, the fenestration template is coupled to the stent graft so that the holes or openings on the fenestration template indicate the fenestration locations.

The application discloses a method for separating and culturing primary vascular smooth muscle cells from human abdominal aortic wall, and relates to the technical field of human cell culture. The method comprises the following steps: obtaining a collagenase A solution; adding the collagenase A solution to a treated human abdominal aortic aneurysm wall tissue sample and then cutting the sample; transferring the cut human abdominal aortic aneurysm wall tissue sample to a 37-degree cell culture box for culture; centrifuging a cell suspension obtained after termination of digestion; discarding supernatant, resuspending cell precipitate, and repeating centrifugation for three times; resuspending the cell precipitate again, uniformly transferring the cell precipitate to a T25 culture bottle after blowing, and placing the cell precipitate in a 37-degree cell culture box for culture; when a wave peak and wave trough state appears, the cell precipitate is digested and subcultured by using 0.25% trypsin, and then the cell precipitate is transferred to a new T25 culture bottle; and the cell precipitate is subcultured normally to the P3 generation and then stored in liquid nitrogen, so that the cell damage is prevented and the activity and proliferation capacity of the cell are maintained.

The invention provides an abdominal aortic aneurysm early prediction model construction method, system and device and a medium. According to the method, a balanced research queue is constructed through fusion of multi-modal data (ultrasonic images, biochemical indexes and lipidomics) and tendency score matching, so that the accuracy of early risk identification of the abdominal aortic aneurysm and the model robustness are remarkably improved; furthermore, on the basis of a risk migration strategy, the discrimination capability of the complex deep learning model is migrated to a simplified logistic regression model which only needs a simplest lipid feature set and basic demographic information, so that high prediction performance is maintained, model lightweight, parameter immobilization and clinical interpretability are realized, the detection cost and the operation complexity are greatly reduced, and the detection efficiency is improved. A high-precision risk prediction technology can be conveniently deployed in a basic medical scene, and finally an abdominal aortic aneurysm early screening solution with high precision, high interpretability and wide applicability is formed.

The utility model discloses a covered stent capable of being used for treating aortic aneurysm diseases, which relates to the technical field of medical instruments and comprises a self-expanding stent, a clamping piece is fixedly connected to the waist line position of an expanding portion of the self-expanding stent, and the clamping piece is made of super-elastic memory alloy. A mode of combining radial force anchoring and structure anchoring is adopted, a part of an anchoring piece is changed into a clamping piece from a traditional barb, the stent moves downwards after arriving at a designed position, the anchoring piece is unfolded and fixed on small blood vessels on two sides, meanwhile, the upper end of the clamping piece is self-expanded and unfolded, double anchoring is carried out, displacement of the stent is avoided, and the stability of the stent is improved. A self-expanding stent is adopted for supporting and an elastic clamping piece and a native blood vessel are clamped for fixing, additional damage is avoided, meanwhile, double-layer polyurethane films are adopted for covering, the anti-leakage capacity is improved while the flexibility is guaranteed, the blood vessel can be prevented from being damaged, and stable support is provided.

The application belongs to the technical field of molecular diagnosis, and particularly relates to a group of extracellular vesicle proteins as biomarkers for diagnosing abdominal aortic aneurysm and application. The application early diagnoses abdominal aortic aneurysm through determination of circulating extracellular vesicle protein markers, and provides an effective tool for diagnosis of abdominal aortic aneurysm. The extracellular vesicle protein marker is any one or two or more molecular marker combinations of interleukin-4 (IL-4), interleukin-6 (IL-6), monocyte chemotactic protein-1 (MCP-1), nerve growth factor (Neurturin) and tumor suppressor M (Oncostatin-M). The application uses proteins in extracellular vesicles as specific markers for early diagnosis of abdominal aortic aneurysm, which is a less applied field in current early diagnosis of AAA. The specific proteins in EVs may be directly related to the pathological process of AAA, and are different from conventional serum markers, and have higher specificity and sensitivity.

The invention relates to an abdominal aortic aneurysm filling system and treatment system, the filling system comprises a filling assembly, the filling assembly comprises at least two filling blocks, each filling block adopts shape memory polymer foam, and each filling block has a compressed loading state and an implantation state of expanding at a preset position; the interventional catheter is used for containing the filling assembly to implement interventional delivery, and the filling blocks are sequentially arranged in the extending direction of the interventional catheter in the loading state; the connecting shaft is arranged in the interventional catheter in a sliding mode, the far-end portion of the connecting shaft sequentially penetrates through and is connected with the filling blocks so as to carry the filling blocks to be released from the far-end side of the interventional catheter into the abdominal aortic aneurysm, and the far-end portion of the connecting shaft is configured to be spirally wound around a space axis in a pre-shaping mode. The surgical operation process is simplified, the filling blocks are arranged relatively orderly after being released and expanded, the space filling rate is high, and the surgical treatment effect is further improved.

Embodiments described herein relate to a shunt for treating an aortic aneurysm and a robotic insertion system for implanting the shunt. In some embodiments, the shunt may include a central portion, an arterial sealing structure, and a venous sealing. In some embodiments, the venous sealing structure may have a lateral length in its deployed configuration, and the arterial sealing structure having a lateral length in its deployed configuration that is greater than the lateral length of the venous sealing structure. The shunt may be advanced robotically in a delivery configuration through a venous puncture site of a vein to access an arterial puncture site of the artery, and then deployed, thereby enabling blood flow through the shunt from the artery to the vein.

The invention discloses application of salvia miltiorrhiza-kudzu vine root vesicle-like nanoparticles, and belongs to the technical field of biological medicines. Salvia miltiorrhiza-kudzu vine root vesicle-like nanoparticles (SPVLNs) are extracted and purified from a salvia miltiorrhiza-kudzu vine root decoction by adopting a differential ultra-high-speed centrifugation method, and the SPVLNs have good blood compatibility, so that when the SPVLNs are applied to treatment of abdominal aortic aneurysm, the SPVLNs can be used for treating abdominal aortic aneurysm, and the SPVLNs can be used for treating abdominal aortic aneurysm. The traditional Chinese medicine composition is capable of obviously relieving thickening of blood vessel walls, reducing infiltration cells of a middle artery membrane and an outer artery membrane, improving reduction and breakage of elastic fibers of the blood vessel walls, increasing extensibility of the elastic fibers of the blood vessel walls, reducing the content of tissue muscle fibers and collagenous fibers and reducing the fibrosis degree of the collagenous fibers; the pathological change, caused by Ang II, of the abdominal aorta of the mouse is obviously improved, and safety and non-toxicity are achieved.

A multi-lumen stent-graft including a graft portion and a stent frame. The stent-graft includes multiple through-channels formed of the graft portion. The graft portion can comprise a PTFE material and the through-channels can be formed of fused portions of the graft portion. The stent-graft can be used in a prostheses that connects multiple vessel branches such as for the repair of aortic aneurysms or other vessels of the body.

The invention belongs to the technical field of medicines, and particularly relates to a prodrug for supplementing NAD < + >, which is an NAMPT agonist YB8, and an application of the prodrug in prevention and treatment of abdominal aortic aneurysm. The invention discloses a prodrug YB8 capable of specifically activating nicotinamide phosphoribosyltransferase (NAMPT), and the prodrug YB8 can effectively improve the level of NAD + (nicotinamide adenine dinucleotide) in cells, so that the degenerative change of a vascular structure is slowed down, the purposes of protecting blood vessels and treating abdominal aortic aneurysm are achieved, and the YB8 is proved to be used as a specific activator of NAMPT for the first time. The multi-target treatment effect is achieved by improving the blood vessel NAD + level; the discovery provides a brand new strategy for the drug treatment of abdominal aortic aneurysm, and the treatment advantages are as follows: ultrasonic imaging proves that the tumor progress can be obviously inhibited; the discovery lays an important foundation for developing clinical treatment of abdominal aortic aneurysm based on NAD + metabolism regulation.

The invention belongs to the technical field of biological medicines, and particularly provides application of prasugrel or pharmaceutically acceptable salts thereof in preparation of medicines for preventing and / or treating aortic aneurysm. The prasugrel or the pharmaceutically acceptable salt thereof is independently used or is combined with other medicines for preventing and / or treating aortic aneurysm. The activity of GLUD1 is enhanced through leucine, so that conversion of Glu to alpha-KG is promoted, degradation of Glu is promoted, namely, the Glu level is reduced by enhancing degradation of Glu, and aortic aneurysm is improved. In a Glu metabolic network, Gln can be converted into Glu under the action of glutaminase 1 (GLS1), so that the generation of Glu is inhibited by inhibiting the activity of GLS1, and the effect of preventing and / or treating aortic aneurysm is achieved.

The invention discloses application of a biomarker in preparation of a product for diagnosing abdominal aortic aneurysm, a kit and a use method, the biomarker has the advantages of high sensitivity, strong specificity and high accuracy, and the detection method is simple and rapid and has important significance in early screening of abdominal aortic aneurysm. The biomarker is any one of the following exosome proteins or a combination thereof: fibrinogen beta chain, fibronectin, lysosome related membrane glycoprotein 2 and histone H4.

A robotic surgical method for repair of an infrarenal aortic aneurysm with an aneurysm sac in an aorta of a patient includes introducing at least one arm and a camera of a robotic surgical system into designated ports of the patient. Then, a graft is attached to a proximal wall of the aorta. The aneurysm sac is decompressed by inflating an intravascular balloon and initiating flow in an arteriovenous circuit. Anterior posterior walls of the aneurysm sac are stapled and the robotic incisions are closed. A method for inserting a conduit includes deploying an intimal umbrella, partially expanding an expandable graft, deploying an adventitial umbrella, and fully inflating the expandable stent.

The invention relates to application of a JAML gene in preparation of an abdominal aortic aneurysm resisting medicine, and belongs to the technical field of biological medicine. The nucleotide sequence of the JAML gene is as shown in SEQ ID No.1. The application of the JAML gene in preparation of the abdominal aortic aneurysm resisting medicine comprises the following two aspects: (1) applying the JAML gene as an action target to preparation of the abdominal aortic aneurysm resisting medicine; and (2) applying the JAML gene as an action target to screening of drugs for resisting abdominal aortic aneurysm. According to the invention, a gene knockout mouse of which the smooth muscle specifically knockout JAML is constructed, and then the mouse abdominal aortic aneurysm model is constructed by subcutaneously pumping AngII, so that the morbidity of abdominal aortic aneurysm can be obviously reduced after the JAML gene is knocked out; therefore, a theoretical basis is provided for preparing or screening drugs or preparations for inhibiting smooth muscle cell JAML gene expression as alternative drugs or preparations for resisting abdominal aortic aneurysm.

The invention provides an application of GPR146 in treatment of abdominal aortic aneurysm. The application proves that the morbidity and mortality of the aortic aneurysm can be effectively reduced by knocking down or knocking out the GPR146; reducing the diameter of the abdominal aorta; the conditions of artery lumen stenosis, vascular structure disorder, remodeling and elastic fiber fracture are reduced. The application provides a new treatment approach beyond surgery for the clinical problem of abdominal aortic aneurysm treatment.

The invention relates to the technical field of image processing, in particular to an abdominal aortic aneurysm intracavitary isolation postoperative internal leakage diagnosis system based on an ultrasound contrast image.According to the method, ultrasound images of different parameters are collected at the same position, firstly, a first ultrasound image is adopted at the high working frequency, and a second ultrasound image is adopted at the high working frequency; then, a second ultrasonic image is collected at low working frequency; the first ultrasonic image and the second ultrasonic image are preprocessed through different preprocessing methods, then the first ultrasonic image is input into an artificial intelligence model to be used for determining the position of the aortic aneurysm, and then the position of the aortic aneurysm in the second ultrasonic image is obtained according to the position; and then inputting the aortic aneurysm in the second image into the artificial intelligence model, thereby realizing internal leakage diagnosis. By means of the mode, the situation that in the prior art, two kinds of ultrasonic images are subjected to image fusion through a complex algorithm and then diagnosis is conducted is avoided, the process is simple, and the diagnosis efficiency is improved.

A stent graft delivery system includes a handle, a guidewire catheter extending distally from the handle, at least one tube, and at least one wire extending through the at least one tube, wherein each wire of the stent graft delivery system is configured as a loop at the distal end of the tube. The stent graft delivery system can be employed to implant stent grafts in a patient to thereby treat, for example, an aortic aneurysm spanning a region of an aorta that includes at least one arterial branch.

The invention relates to the technical field of medical instruments, in particular to an abdominal aortic aneurysm cavity support auxiliary positioning device. An inner tube and a positioning assembly are coaxially arranged in the outer sheath tube in a sleeving manner; the outer sheath tube is connected with the near end of the inner tube, so that the relative positions of the outer sheath tube and the inner tube can be kept consistent; the positioning assembly is arranged on the periphery of the inner tube in a sleeving mode and can slide between the outer sheath tube and the inner tube. A penetrating through hole is formed in the center of the inner tube, and a guide wire can penetrate through the penetrating through hole and slide in the inner tube. The auxiliary positioning device for the abdominal aortic aneurysm cavity support is simple in structure, easy and convenient to operate and capable of effectively assisting in positioning a main body support short iliac branch opening in an abdominal aortic aneurysm cavity, the butt joint efficiency of the main body support short iliac branch and an iliac branch extension support is improved, the operation time is shortened, the operation risk is reduced, and ray damage is reduced.